Wang, Tao
Kuang, Weihong
Chen, Wei
Xu, Wenwei
Zhang, Liming
Li, Yingjie
Li, Hailin
Peng, Ying
Chen, Yangmei
Wang, Baojun
Xiao, Jinsong
Li, Honghua
Yan, Chuanzhu
Du, Yifeng
Tang, Mouni
He, Zhiyi
Chen, Haibo
Li, Wei
Lin, Hong
Shi, Shugui
Bi, Jianzhong
Zhou, Huadong
Cheng, Yan
Gao, Xiaoping
Guan, Yihui
Huang, Qiu
Chen, Kewei
Xin, Xianliang
Ding, Jian
Geng, Meiyu
Xiao, Shifu https://orcid.org/0000-0002-4721-9646
Funding for this research was provided by:
National Major Scientific and Technological Special Project (2011ZX09101-003-01)
National High Technology Research and Development Program of China (2006AA090501)
Article History
Received: 2 July 2020
Accepted: 2 September 2020
First Online: 14 September 2020
Ethics approval and consent to participate
: The trial protocol was approved by the Ethics Review Board of Shanghai Mental Health Center (Shanghai, China). The trial protocol was approved by the Institutional Review Boards of all participating sites. All participants or their representatives provided written informed consent before participation in the trial.
: All authors approved the final version of the manuscript for submission.
: Shifu Xiao has been a provisional consultant of Pfizer, Lilly, Novartis, GSK, Johnson & Johnson, Lundbeck, and Green Valley and received honorariums. Kewei Chen was a paid consultant and a full-time employee of Shanghai Green Valley Pharmaceutical Co., Ltd. at the time the FDG-PET data was analyzed, and the time the manuscript was prepared respectively. Currently, he is a full-time employee of Banner Health to which Banner Alzheimer’s Institute belongs, and serves as a paid consultant to Shanghai Green Valley Pharmaceutical Co., Ltd. Xianliang Xin is a full-time employee of the Shanghai Green Valley Pharmaceutical Co Ltd. Part of the results of this paper was presented at the 7th Clinical Trials Conference on Alzheimer’s Disease (CTAD) November 20–22, 2014, Philadelphia, PA, USA.